News

Innovative Partnership Between DoorDash and Criteo to Boost Retail Media

Innovative Partnership Between DoorDash and Criteo to Boost Retail Media

Enhancing Retail Media Through Innovation

Criteo S.A. (NASDAQ: CRTO) and DoorDash, Inc. (NASDAQ: DASH) have announced a groundbreaking collaboration aimed at revolutionizing advertising within the retail media landscape. This partnership opens new avenues for brands looking to engage with consumers on DoorDash's platform, which includes grocery and other non-restaurant sectors.

Collaboration Focused on Media Placement

As part of this agreement, Criteo will serve as an extension of DoorDash's U.S. advertising sales team. The primary objective is to work directly with brands and agencies, enhancing their media placements across the DoorDash platform. This collaboration signifies a significant step towards integrating their advertising technologies for a streamlined marketing approach.

Capitalizing on Retail Media Growth

The partnership takes advantage of the rapid expansion of retail media, recognized as one of the most dynamic segments in digital advertising today. It offers brands innovative strategies to connect with consumers at crucial points in their purchasing journey, particularly as online shopping continues to gain traction.

Widening Advertising Opportunities

Advertisers who collaborate with Criteo will benefit from a range of DoorDash's advertising formats, including on-site video ads, display banners, and options like Sponsored Products and Sponsored Brands. Additionally, this partnership extends to off-site channels, such as display, video, search, and social media, creating a comprehensive advertising ecosystem.

Expert Insights on the Partnership

Stephen Howard-Sarin, Managing Director of Retail Media Americas at Criteo, expressed enthusiasm about the venture, stating, "This is an exciting moment for Criteo, DoorDash, and the advertisers and retailers we serve. Delivery is the most important new path in the CPG consumer journey, and DoorDash has become a must-buy destination for convenience, grocery, and alcohol brands." His statement emphasizes the potential impact of this partnership on the consumer journey.

Expected Outcomes for Advertisers

According to Howard-Sarin, this collaboration aims to empower advertisers to connect with consumers more effectively. The goal is not only to drive measurable sales but also to influence buying behavior and streamline retail media strategies between delivery marketplaces and retailer websites.

Strategic Vision from DoorDash

From the DoorDash side, John Roswech, Head of Business for Symbiosys, shared that the company's ad platform is designed to help businesses thrive both on DoorDash and across other channels. He highlighted Criteo's strength in building relationships with brands and agencies across various retail categories, which is pivotal for expanding engagement opportunities at relevant consumer touchpoints.

Investors' Response

The announcement has already prompted a positive response from the market, with CRTO shares increasing by 2.78% to $22.15, while DASH shares rose by 0.53% to $272.67 before market opening. This reflects investor confidence in the potential of the collaboration to enhance growth prospects for both companies.

Looking Ahead in Retail Media

The partnership between Criteo and DoorDash is set to reshape the advertising landscape, particularly in the retail media sector. As consumers increasingly turn to online platforms for their shopping needs, this alliance positions both companies to capitalize on evolving market trends, ensuring they remain at the forefront of advertising innovation.

Frequently Asked Questions

What is the main goal of the Criteo and DoorDash partnership?

The partnership aims to enhance advertising opportunities across DoorDash's platform, focusing on efficiency and integration of technologies for brands.

How will advertisers benefit from this collaboration?

Advertisers will gain access to various ad formats and off-site channels, allowing for more effective consumer engagement and measurable sales.

Who are the key executives involved in this deal?

Stephen Howard-Sarin from Criteo and John Roswech from DoorDash are the key executives highlighting the strategic vision of the partnership.

What impact could this partnership have on the retail media landscape?

The collaboration could significantly influence the dynamics of retail media by providing brands new ways to connect with consumers closer to the point of purchase.

How have investors reacted to this announcement?

Investors have responded positively, as reflected in the increased share prices of both Criteo and DoorDash upon the announcement of their partnership.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 3

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
More News Articles